Equities

Anagenics Ltd

AN1:ASX

Anagenics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.008
  • Today's Change0.00 / 0.00%
  • Shares traded93.85k
  • 1 Year change-57.89%
  • Beta-1.4990
Data delayed at least 20 minutes, as of Aug 29 2024 06:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anagenics Limited is an Australia-based health and beauty-tech company. The Company offers a range of clinically validated anti-ageing and wellness products developed in-house or sourced from premium international brands. The Company, through its wholly owned subsidiary Advangen Pty Ltd, develops, manufactures and markets anti-aging products globally, with its FGF5 inhibitor hair health and hair growth products sold worldwide. The flagship anti-aging hair care range, marketed as evolis, Advangen Jo-Ju and Lexilis brands, is sold in Japan, the United States of America and Australia. The Company’s subsidiary is BLC Cosmetics Pty Limited, which is the distributor of international and local skin care and wellbeing brands.

  • Revenue in AUD (TTM)10.80m
  • Net income in AUD-7.54m
  • Incorporated2004
  • Employees--
  • Location
    Anagenics LtdSuite 204, Level 2, 55 Clarence StreetSYDNEY 2000AustraliaAUS
  • Phone+61 29221-6830
  • Fax+61 29221-8535
  • Websitehttps://anagenics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Skin Elements Ltd416.21k-1.87m2.36m--------5.67-0.0033-0.00330.0007-0.00150.34120.93850.7643---153.61-50.37---57.7186.9569.51-450.21-725.460.4493-19.67----114.39-12.2183.59------
Klinko Karya Imaji PT Tbk2.14m205.58k2.79m4.0013.570.84087.101.301.621.6216.8726.170.51043.4711.865,522,168,000.004.90--5.08--45.67--9.60--7.443.430.2018--125.71--143.88------
Anagenics Ltd10.80m-7.54m3.69m----1.36--0.3416-0.0181-0.01880.02710.00591.233.3312.74---85.81-31.62-121.35-41.2740.3752.77-69.75-47.680.7609-61.850.2219--18.547.67-332.64--8.31--
Data as of Aug 29 2024. Currency figures normalised to Anagenics Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.